Povetacicept: IgAN accelerated-approval decision
Vertex confirmed November 30, 2026 as the FDA target for potential accelerated approval of povetacicept in adult IgAN in its October RAINIER update. This is the IgAN BLA, not a primary membranous nephropathy application or a question about already published interim trial success.
What matters
Follow the exact application, indication and requested label. An FDA decision concerns the drug program, while the company’s stock also reflects its other assets and business.
- Specify whether accelerated approval qualifies for YES; the candidate wording includes it.
- Primary membranous nephropathy and IgAN are distinct indications. Positive RAINIER data are already disclosed and are not a pending binary readout.
Primary evidence
FDA target 2026-11-30 — not a guaranteed decision date
Potential outcome market
Will FDA approve povetacicept for adults with immunoglobulin A nephropathy by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.